Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of ...

Data demonstrate that MTX-201 binds CD8 Treg, selectively eliminates pathogenic CD4 T cells, and may decrease inflammation ...

Eli Lilly (LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to ...

Kendall Markovic was a leader on and off the field when Hutchinson’s girls and boys soccer teams played host to Rockford Tuesday. The senior co-captain started as a mid-fielder, plus helped ...

INTERCEPT will recruit 10,000 healthy first-degree relatives of individuals with Crohn's disease from seven European countries to validate biomarkers and risk score. Of these, 80 people at the ...

The results of the RELIEVE UCCD study in patients with moderate-to-severe ulcerative colitis (UC) and Crohn's disease suggest a "best-in-class potential" for the drug, which Sanofi licensed from ...

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...

Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...

Learn more about whether Option Care Health, Inc. or Surgery Partners, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Let's dive deep into a topic that isn’t getting enough shine – Crohn's disease and how it's hitting the Black community.